Contemporary Primary Treatment of Women With Stage II-IV Low-Grade Serous Ovarian/Peritoneal Cancer (Lgsoc): Determinants of Relapse and Disease-Free Survival

Authors

David M Gershenson
Lauren P Cobb
Shannon N Westin
Yingao Zhang
Amir Jazaeri
Anais Malpica
Charlotte C Sun

Publication Date

11-1-2022

Journal

Gynecologic Oncology

Abstract

Objective: The purpose of the present study is to describe a cohort who received contemporary primary treatment for stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC), including patient characteristics and determinants of relapse and disease-free survival.

Methods: The study included 99 patients: 1) with pathologically confirmed stage II-IV LGSOC of the ovary or peritoneum, 2) who underwent primary treatment consisting of cytoreductive surgery and either a) platinum/taxane chemotherapy followed by aromatase inhibitor maintenance therapy or b) aromatase inhibitor monotherapy, and 3) for whom there was availability of clinical data. Descriptive statistics were used to characterize clinicodemographic features. Subgroups were compared for PFS and OS. Multivariable Cox regression analyses were performed.

Results: Median PFS for the entire cohort was 56.8 months (95% CI, 41.3-NE), and median OS was 130.7 months (95% CI, 115.0-146.4). Forty-nine of 99 (49.5%) patients have relapsed to date. For these 49 patients, median time from diagnosis to relapse was 29.6 months (95% CI, 24.6-33.1) (range, 5.4-69.1 months). Only 1/49 (2%) patients who relapsed did so >5 years from diagnosis. Fifty (50.0%) patients have not experienced disease progression or relapse. Median follow-up time for these 50 patients is 86.2 months (range, 25.3-169.0). Thirty-three of the 50 (66.0%) have been followed for >5 years from diagnosis. On regression analyses, factors associated with improved patient outcomes-either PFS, OS, or both-included no gross residual disease, normal serum CA 125 at diagnosis, primary peritoneal site, and presence of extensive psammomatous calcifications.

Conclusions: This is the first report to describe the clinicopathologic features and outcomes of women with stage II-IV LGSOC who received contemporary primary therapy.

Keywords

Humans, Female, Disease-Free Survival, Peritoneum, Aromatase Inhibitors, Neoplasm Recurrence, Local, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Cystadenocarcinoma, Serous, Retrospective Studies, Aromatase inhibitor, Chemotherapy, Low-grade serous carcinoma, Ovary, Peritoneum

DOI

10.1016/j.ygyno.2022.09.005

PMID

36137845

PMCID

PMC12073492

PubMedCentral® Posted Date

5-13-2025

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes